Interleukin-13 as a potential biomarker in the management of pediatric asthma – a longitudinal study
DOI:
https://doi.org/10.15584/ejcem.2025.1.3Keywords:
asthma, biomarkers, interleukin-13Abstract
AbstractIntroduction and aim. Asthma is predominantly a Th2 type hypersensitive disorder, with interleukin (IL) 4 and IL-13 playing a pivotal roles. Interleukin 13 is one of several cytokines that cause persistent inflammation associated with asthma. The aim was to examine the relationship between the response to treatment in asthma and serum IL-13.
Material and methods. This study, conducted at the SRM Medical College Hospital and Research Center, in Tamil Nadu, in volved 68 children aged 6 to 12 years of age diagnosed with asthma. The study included medical history, including age of onset of wheezing, history of allergic rhinitis/atopic dermatitis, food allergies, use of inhalational corticosteroids, hospital admissions, and family history. Spirometry was performed, and treatment with inhalational corticosteroids was started according to GINA guidelines. Blood was collected prior to and after 3 months of treatment.
Results. A substantial positive correlation was observed between gender and IL-13 levels. An improvement in forced expirato ry volume in the first second (FEV1) was observed after treatment [(74.72% vs 95.05%) (p<0.0001)]. A negative correlation was discovered between IL-13 and FEV1. A statistical significance between IL-13 levels before and after treatment (p=0.005).
Conclusion. Inhalational corticosteroids reduced serum IL-13 levels, indicating its role as a prognostic marker in pediatric asthma.
Downloads
References
Lizzo JM, Cortes S. Pediatric Asthma. In: StatPearls. Treasure Island (FL): StatPearls, 2023. https://www.ncbi.nlm.nih.gov/books/NBK551631/. Accessed February 20, 2024.
Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol. 2010;28:445-489. doi: 10.1146/annurev-immunol-030409-101212
Wills-Karp M, Chiaramonte M. Interleukin-13 in asthma. Curr Opin Pulm Med. 2003;9(1):21-27. doi: 10.1097/00063198-200301000-00004
Kraft M. Asthma phenotypes and interleukin-13-moving closer to personalized medicine. N Engl J Med. 2011;365(12):1141-1144. doi: 10.1056/NEJMe1108666
Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21:425-456. doi: 10.1146/annurev.immunol.21.120601.141142
National Institutes of Health. National Asthma Education and Prevention Program Expert Panel Report 3:Guidelines for the Diagnosis and Management of Asthma. Accessed January 1, 2009.
Clinical Pulmonary Function Testing, Exercise Testing, and Disability Evaluation. George RB, Light RW, Matthay RA, Matthay MA, editors. In Chest Medicine: Essentials Of Pulmonary And Critical Care Medicine. (5th edition) 2005 May.
Biesiadecki M, Galiniak S, Bartusik-Aebisher D, Aebisher D. Receiver operating characteristic analysis of the FeNO biomarker in the diagnosis of asthma. Eur J Clin Exp Med. 2018;16(4):253-258. doi: 10.15584/ejcem.2018.4.1
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. www.ginaasthma.org. Assessed January 20, 2022.
Johnson JD, Theurer WM. A stepwise approach to the interpretation of pulmonary function tests. Am Fam Physician. 2014;89:359-366.
Lahoda D, Velychko V. Dynamics of changes in the level of IgA in patients with bronchial asthma against the background of excessive body weight or obesity. Eur J Clin Exp Med. 2019;17(3):203-208. doi: 10.15584/ejcem.2019.3.1
Popović-Grle S, Štajduhar A, Lampalo M, Rnjak D. Biomarkers in Different Asthma Phenotypes. Genes. 2021;12(6):801. doi: 10.3390/genes12060801
Chung KF. Precision medicine in asthma: Linking phenotypes to targeted treatments. Curr. Opin Pulm Med. 2018;24:4-10.
Rael EL, Lockey RF. Interleukin-13 signaling and its role in asthma. World Allergy Organ J. 2011;4(3):54-64. doi: 10.1097/WOX.0b013e31821188e0
Javaid K, Nadeem A, Adhami SUZ, et al. Positive correlation of serum interleukin-13 and total immunoglobulin E in bronchial asthma patients. Bangladesh Journal of Medical Science. 2022;21(3):596–600. doi: 10.3329/bjms.v21i3.59573
Jebur MS, Saud AM. Serum Levels of Total IgE and Interleukin-13 in a Sample of Allergic Asthma Patients in Baghdad. Iraqi Journal of Science. 2020;61(12):3208–3214. doi: 10.24996/ijs.2020.61.12.8
Janeva EJ, Goseva Z, Gjorchev A, et al. The Effect of Combined Therapy ICS/LABA and ICS/LABA plus Montelukast in Patients with Uncontrolled Severe Persistent Asthma Based on the Serum IL-13 and FEV1. Open Access Maced J Med Sci. 2015;3(2):268-272. doi: 10.3889/oamjms.2015.053
Gemou-Engesaeth V, Laliotou N, Corrigan CJ, Chrousos GP, Haczku A. Serum Interleukin 13 (IL-13) and Surfactant Protein D (SP-D) Expression Is Differentially Associated With Disease Status In Pediatric Asthma Patients. Journal of Allergy and Clinical Immunology. 2014;133(2):AB148. doi: 10.1016/j.jaci.2013.12.543
Bagnasco D, Ferrando M, Varricchi G, Passalacqua G, Canonica GW. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma. International Archives of Allergy and Immunology. 2016;170(2):122-131. doi: 10.1159/000447692
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
